I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
IMAB Stock | USD 0.95 0.01 1.06% |
About 52% of I Mab's investor base is interested to short. The analysis of the overall investor sentiment regarding I Mab suggests that many traders are impartial. The current market sentiment, together with I Mab's historical and current headlines, can help investors time the market. In addition, many technical investors use I Mab stock news signals to limit their universe of possible portfolio assets.
IMAB |
I-Mab , a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced a poster presentation highlighting encouraging top-line results from its ongoing Phase 1 clinical study of givastomig, a novel first-in-class Claudin18.2 and 4-1BB bispecific antibody immunostimulant, in patients with advanced cancers, especially gastric cancers including
Read at finance.yahoo.com
I Mab Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards I Mab can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
I Mab Fundamental Analysis
We analyze I Mab's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of I Mab using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of I Mab based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
I Mab is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
I Mab Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with I Mab stock to make a market-neutral strategy. Peer analysis of I Mab could also be used in its relative valuation, which is a method of valuing I Mab by comparing valuation metrics with similar companies.
Peers
I Mab Related Equities
DSGN | Design Therapeutics | 9.43 | ||||
STTK | Shattuck Labs | 6.93 | ||||
ASND | Ascendis Pharma | 2.87 | ||||
APLS | Apellis Pharmaceuticals | 2.26 | ||||
RVMD | Revolution Medicines | 1.97 | ||||
CGEM | Cullinan Oncology | 1.83 | ||||
GLUE | Monte Rosa | 1.65 | ||||
LYEL | Lyell Immunopharma | 1.10 | ||||
KRYS | Krystal Biotech | 1.01 | ||||
IMVT | Immunovant | 1.00 | ||||
BGNE | BeiGene | 0.95 | ||||
BPMC | Blueprint Medicines | 0.81 | ||||
ERAS | Erasca | 0.72 | ||||
NRIX | Nurix Therapeutics | 0.14 | ||||
AKRO | Akero Therapeutics | 1.92 | ||||
KYMR | Kymera Therapeutics | 2.21 | ||||
FHTX | Foghorn Therapeutics | 4.81 |
Complementary Tools for IMAB Stock analysis
When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |